1927-95-3

Basic information

• Product Name: 4-BROMOPHENOL ACETATE
• Synonyms: p-bromophenylacetate;Phenol, p-bromo-, acetate;4-BROMOPHENYLACETATE;4-BROMOPHENOL ACETATE;4-Bromophenylacetate, 98 %;4-Bromo-1-acetoxybenzene;Acetic acid p-bromophenyl ester;(4-bromophenyl) ethanoate
• CAS NO: 1927-95-3
• Molecular Formula: C8H7BrO2
• Molecular Weight: 215.04
• EINECS: 217-668-6
• Product Categories: Aromatics;Miscellaneous Reagents
• Mol File: 1927-95-3.mol
• Article Data: 127

Chemical Properties

• Melting Point: 21.5 °C
• Boiling Point: 251℃
• Flash Point: 106℃
• Appearance: white like or light brown crystalline powder
• Density: 1.501
• Vapor Pressure: 0.0211mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-BROMOPHENOL ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMOPHENOL ACETATE(1927-95-3)
• EPA Substance Registry System: 4-BROMOPHENOL ACETATE(1927-95-3)

Safety Data

• Hazardous Substances Data: 1927-95-3(Hazardous Substances Data)

Usage

General Description

4-Bromophenol acetate is a chemical compound that consists of a benzene ring with a bromine atom and a hydroxyl group attached, as well as an acetate group. It is often used as a building block in organic synthesis, particularly in the production of pharmaceuticals and agrochemicals. The presence of the bromine atom makes it useful for conducting various reactions, such as nucleophilic substitution and Suzuki coupling. Additionally, the acetate group can serve as a leaving group in certain reactions. 4-Bromophenol acetate is a versatile compound that has a range of potential applications in the chemical industry.

InChI:InChI=1/C8H7BrO2/c1-6(10)11-8-4-2-7(9)3-5-8/h2-5H,1H3

Upstream product

• 99-90-1 para-bromoacetophenone 
• 106-41-2 4-bromo-phenol 
• 243990-72-9 acetic acid 1-(2,5-dichloro-phenyl)-2,2-bis-methylsulfanyl-vinyl ester 
• 506-96-7 Acetyl bromide 
• 4887-24-5 triacetoxyborane 
• 108-86-1 bromobenzene 
• 3240-34-4 [bis(acetoxy)iodo]benzene 
• 108-24-7 acetic anhydride 
• 77-48-5 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione 
• 122-79-2 Phenyl acetate 
• 56-23-5 tetrachloromethane 
• 128-08-5 N-Bromosuccinimide 
• 589-87-7 1,4-bromoiodobenzene 
• 6018-89-9 nickel(II) acetate tetrahydrate 

Downstream Products

• 51035-40-6 4-pyridin-2-yl-phenol 
• 25244-30-8 4-(allyloxy)bromobenzene 
• 25458-45-1 p-methoxymethoxybromobenzene 
• 67963-68-2 t-butyldimethylsilyl-4-bromophenol 
• 1450-75-5 5-Bromo-2-hydroxyacetophenone 
• 109669-49-0 2,2'-bis(5,6-dihydro-4H-pyran) 
• 2759-56-0 p-isopropenyl-phenol acetate 
• 2628-16-2 p-acetoxystyrene 
• 42206-94-0 triacetyl-trans-resveratrol 
• 501-36-0 (E)-5-[2-4-(hydroxyphenyl)ethenyl]-1,3-benzenediol 
• 1064704-94-4 1-(4-(piperidin-1-yl)phenyl) acetate 
• 1032324-90-5 C₈H₇BrO₂Zn 
• 4139-61-1 6-bromo-4-hydroxycoumarin 
• 1404189-34-9 C₁₇H₁₀BrN₃O₂ 

Relevant articles and documents

Chromone dioxadiazole compound as well as preparation method and application thereof

The preparation method comprises the following steps: adding an intermediate F and bis (acetoxy) iodobenzene to dichloromethane for reaction to obtain the chromone compound. The invention provides a novel chromone dioxadiazole compound and a preparation method thereof, and overcomes the defects of large toxicity and high preparation cost of the traditional method.

Synthesis and anti-inflammatory activity of 2-oxo-2H-chromenyl and 2H-chromenyl-5-oxo-2,5-dihydrofuran-3-carboxylates

Cycloaddition reaction of 4-chloro-2-oxo-2H-chromene-3-carbaldehydes (3a-g) and 4-chloro-2H-chromene-3-carbaldehydes (7a-h) with activated alkynes (4a-b) provided the 2-oxo-2H-chromenyl-5-oxo-2,5-dihydrofuran-3-carboxylates (5a-n) and 2H-chromenyl-5-oxo-2,5-dihydrofuran-3-carboxylates (8a-p). All the prepared compounds were screened for anti-inflammatory activity. In vitro anti-inflammatory activity data demonstrated that the compounds 5g, 5i, 5k-l and 8f are effective among the tested compounds against TNF-α (1.108 ± 0.002, 0.423 ± 0.022, 0.047 ± 0.001, 0.070 ± 0.002 and 0.142 ± 0.001 μM) in comparison with standard compound Prednisolone (0.033 ± 0.002 μM). Based on in vitro results, three compounds (5i, 5k and 8f) have been selected for in vivo experiments and these compounds are identified as better compounds with respect to anti-inflammatory activity in LPS induced mice model. Compound 5i was identified as potent and showed significant reduction in TNF-α and IL-6.

(4-HYDROXYPYRROLIDIN-2-YL)-HYDROXAMATE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to bifunctional compounds, which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which binds to the VHL E3 ubiquitin ligase, and on the other end a moiety that binds a target protein such that degradation of the target protein/polypeptide is effectuated. Also disclosed are VHL ligands.